Tranzyme And BMS Sign Discovery Deal | December 14, 2009 Issue - Vol. 87 Issue 50 | Chemical & Engineering News
Volume 87 Issue 50 | p. 20 | Concentrates
Issue Date: December 14, 2009

Tranzyme And BMS Sign Discovery Deal

Department: Business
Keywords: Tranzyme Pharma, macrocyclic compounds

Tranzyme Pharma will work to discover macrocyclic compounds directed against targets that are of interest to Bristol-Myers Squibb. BMS will pay $10 million up front and between $3 million and $6 million in R&D funding for two years. BMS will be primarily responsible for optimizing any lead compounds, as well as for further development. Tranzyme could receive milestone payments of up to $80 million for each target program. Tranzyme uses macrocyclic template chemistry to find novel bioactive macrocycles that have the potency and selectivity of biomolecules but the low production costs and high oral availability of small-molecule drugs.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment